{"preliminary_commentary":{"by_channel":{"youtube":10,"podcast":10,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03625037\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["epcoritamab"]],"indication":"relapsed or refractory B-cell non-Hodgkin lymphoma","name":"EPCORE NHL-1","nct_id":"NCT03625037","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-nhl-1-nct03625037. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EPCORE™ NHL-1","arms":[{"description":"Epcoritamab will be administered by subcutaneous injections in cycles of 28 days.","label":"Epcoritamab","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2029-01","type":"ESTIMATED"},"conditions":["DLBCL","High-grade B-cell Lymphoma (HGBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","FL","MCL","Small Lymphocytic Lymphoma (SLL)","Marginal Zone Lymphoma (MZL)","Indolent B-cell Non-Hodgkin Lymphoma (iNHL)","Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)"],"enrollment":{"count":666,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"}],"last_update":"2026-10-06","lead_sponsor":"Genmab","official_title":"A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2029-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-Escalation: Dose Limiting Toxicity (DLT)","timeFrame":"During the first cycle (28 days)"},{"measure":"Dose-Escalation: Number of Participants with Adverse Events (AEs)","timeFrame":"From first dose until the end of the safety follow-up period (Up to 1 year)"},{"measure":"Expansion: Overall Response Rate (ORR)","timeFrame":"Up to 1.5 years"},{"measure":"Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS Events","timeFrame":"From first dose until 7 days after second full dose (Day 28 for DLBCL; Day 35 for FL; Day 28-35 for MCL)"}],"references":[{"citation":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.","pmid":"36548927","type":"RESULT"},{"citation":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R, Lewis DJ, Okada C, Hutchings M, Clausen MR, Sancho JM, Cochrane T, Leppa S, Chamuleau MED, Gernhardt D, Altintas I, Liu Y, Ahmadi T, Dinh MH, Hoehn D, Favaro E, Elliott B, Thieblemont C, Vose JM. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024 Aug;11(8):e593-e605. doi: 10.1016/S2352-3026(24)00166-2. Epub 2024 Jun 15.","pmid":"38889737","type":"RESULT"},{"citation":"Sinnollareddy M, Sanghavi K, Gibiansky L, Li T, Putnins M, Mohamed MF, Patah P, Favaro E, Gupta M, Parikh A, Xu S. Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma. Clin Pharmacokinet. 2026 Aug 1. doi: 10.1007/s40262-026-01661-1. Online ahead of print.","pmid":"42541678","type":"DERIVED"},{"citation":"Altintas I, Morehouse C, Favaro E, Rana A, Karavitis J, Szafer-Glusman E, Zhao K, Linton K, Danilov A, LaCasce AS, Falchi L, Okosun J, Ahmadi T, Fereshteh M, Jure-Kunkel M, Soong D, Steele AJ. MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. Blood Adv. 2026 Oct 13;10(19):6381-6394. doi: 10.1182/bloodadvances.2025017565.","pmid":"42431612","type":"DERIVED"},{"citation":"Li T, Tredennick A, Polhamus D, Putnins M, Liu S, Sanghavi K, Thalhauser CJ, Parikh A, Noorani B, Mohamed MF, Le Gallo C, Elliott B, Gupta M, Xu S. Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. Clin Pharmacol Ther. 2026 Aug;120(2):542-551. doi: 10.1002/cpt.70362. Epub 2026 Jul 7.","pmid":"42411504","type":"DERIVED"},{"citation":"Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.","pmid":"40472301","type":"DERIVED"},{"citation":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25.","pmid":"39322711","type":"DERIVED"},{"citation":"Phillips T, Lugtenburg P, Kalsekar A, Mutebi A, Wang A, Blaedel J, Kosa K, Martin S, Sacchi M, Kilavuz N, Thieblemont C. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e78-e87.e2. doi: 10.1016/j.clml.2023.11.005. Epub 2023 Nov 27.","pmid":"38151388","type":"DERIVED"},{"citation":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.","pmid":"34508654","type":"DERIVED"}],"start_date":{"date":"2018-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT03625037"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-nhl-1-nct03625037"}